GLP-1 and its analogs also have potent effects on blood pressure, and may therefore play a role in ameliorating hypertension
This science-backed method revolves around activating key arousal pathways with an FDA-approved peptide: PT-141 (bremelanotide), commonly known as the "Pink Shot." It addresses hypoactive sexual desire disorder (HSDD) by stimulating brain receptors involved in sexual motivation, leading to increased desire, better lubrication, heightened sensitivity, reduced pain during intercourse, and greater overall satisfactionwithout directly altering hormones.[1][2][3] Clinical trials show it can significantly improve sexual function scores in premenopausal women with HSDD, with up to 51% reporting enhanced desire compared to placebo groups, but its benefits extend to perimenopausal and postmenopausal women dealing with vaginal atrophy and low libido.[1] Weve long known that peptides can influence sexual health, but PT-141 stands out as the first FDA-approved injectable specifically for HSDD in women
This ensures the safe and effective administration of the vitamin
Disclosures Yousef Al-Saleh received speaker honoraria and was part of advisory boards of the following pharmaceutical companies: Eli Lilly, Novo Nordisk, Servier, Boehringer Ingelheim, Abbott, Astra Zeneca, Sanofi-Aventis and Novartis
